PHARMACOLOGICAL RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：单体;中药;综述 经验分享：投稿审完，Decision in Process已经两个月了还没返回意见，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0 偏重的研究方向：单体;综述 经验分享：7.4 投稿 7.5 拒稿，建议修改标题，并补充 7.12 修改后Submitted to Journal 7.12 With Editor 7.12 Under Review 8.12 三个审稿人意见返回，Required Reviews Completed，最后回了三个意见 8.12 晚上 Major Revise (20天期限) 8.30 With Editor 9.1 Under Review 9.3 两个审稿人意见返回 9.3 Decision in Process 9.8 Accept 投稿后拒稿在次投稿，希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向：靶向治疗;药理;综述 经验分享：6月21号晚上投稿，综述看下什么情况，能中的话会回来评论另外想问下各位投稿稿件号都到多少了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0 偏重的研究方向：机制;药效;疗效 经验分享：required reviews completed状态持续5天了，好久了，是因为过元旦吗，有没有类似情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了，请问有类似情况的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=)]

2024-02-28 不死鸟的飞翔来自重庆

偏重的研究方向：肿瘤
经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收

20 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：单体;中药;综述 经验分享：投稿审完，Decision in Process已经两个月了还没返回意见，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0 偏重的研究方向：单体;综述 经验分享：7.4 投稿 7.5 拒稿，建议修改标题，并补充 7.12 修改后Submitted to Journal 7.12 With Editor 7.12 Under Review 8.12 三个审稿人意见返回，Required Reviews Completed，最后回了三个意见 8.12 晚上 Major Revise (20天期限) 8.30 With Editor 9.1 Under Review 9.3 两个审稿人意见返回 9.3 Decision in Process 9.8 Accept 投稿后拒稿在次投稿，希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向：靶向治疗;药理;综述 经验分享：6月21号晚上投稿，综述看下什么情况，能中的话会回来评论另外想问下各位投稿稿件号都到多少了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0 偏重的研究方向：机制;药效;疗效 经验分享：required reviews completed状态持续5天了，好久了，是因为过元旦吗，有没有类似情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了，请问有类似情况的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=)]

2023-09-07 ms7000000804202809 来自四川省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：单体;中药;综述
经验分享：投稿审完，Decision in Process已经两个月了还没返回意见，这正常吗

0 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：单体;中药;综述 经验分享：投稿审完，Decision in Process已经两个月了还没返回意见，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0 偏重的研究方向：单体;综述 经验分享：7.4 投稿 7.5 拒稿，建议修改标题，并补充 7.12 修改后Submitted to Journal 7.12 With Editor 7.12 Under Review 8.12 三个审稿人意见返回，Required Reviews Completed，最后回了三个意见 8.12 晚上 Major Revise (20天期限) 8.30 With Editor 9.1 Under Review 9.3 两个审稿人意见返回 9.3 Decision in Process 9.8 Accept 投稿后拒稿在次投稿，希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向：靶向治疗;药理;综述 经验分享：6月21号晚上投稿，综述看下什么情况，能中的话会回来评论另外想问下各位投稿稿件号都到多少了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0 偏重的研究方向：机制;药效;疗效 经验分享：required reviews completed状态持续5天了，好久了，是因为过元旦吗，有没有类似情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了，请问有类似情况的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=)]

2022-12-04 1241217bm20暂无昵称来自江苏省

这周刚接受了一篇，速度很快，很爽！！

59 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：单体;中药;综述 经验分享：投稿审完，Decision in Process已经两个月了还没返回意见，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0 偏重的研究方向：单体;综述 经验分享：7.4 投稿 7.5 拒稿，建议修改标题，并补充 7.12 修改后Submitted to Journal 7.12 With Editor 7.12 Under Review 8.12 三个审稿人意见返回，Required Reviews Completed，最后回了三个意见 8.12 晚上 Major Revise (20天期限) 8.30 With Editor 9.1 Under Review 9.3 两个审稿人意见返回 9.3 Decision in Process 9.8 Accept 投稿后拒稿在次投稿，希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向：靶向治疗;药理;综述 经验分享：6月21号晚上投稿，综述看下什么情况，能中的话会回来评论另外想问下各位投稿稿件号都到多少了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0 偏重的研究方向：机制;药效;疗效 经验分享：required reviews completed状态持续5天了，好久了，是因为过元旦吗，有没有类似情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了，请问有类似情况的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=)]

2023-09-22 ms6000002095545543 来自河南省

想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗

28 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：单体;中药;综述 经验分享：投稿审完，Decision in Process已经两个月了还没返回意见，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0 偏重的研究方向：单体;综述 经验分享：7.4 投稿 7.5 拒稿，建议修改标题，并补充 7.12 修改后Submitted to Journal 7.12 With Editor 7.12 Under Review 8.12 三个审稿人意见返回，Required Reviews Completed，最后回了三个意见 8.12 晚上 Major Revise (20天期限) 8.30 With Editor 9.1 Under Review 9.3 两个审稿人意见返回 9.3 Decision in Process 9.8 Accept 投稿后拒稿在次投稿，希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向：靶向治疗;药理;综述 经验分享：6月21号晚上投稿，综述看下什么情况，能中的话会回来评论另外想问下各位投稿稿件号都到多少了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0 偏重的研究方向：机制;药效;疗效 经验分享：required reviews completed状态持续5天了，好久了，是因为过元旦吗，有没有类似情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了，请问有类似情况的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=)]

2022-09-08 待我慢慢

审稿速度:2.0
偏重的研究方向：单体;综述
经验分享：7.4 投稿
7.5 拒稿，建议修改标题，并补充
7.12 修改后Submitted to Journal
7.12 With Editor
7.12 Under Review
8.12 三个审稿人意见返回，Required Reviews Completed，最后回了三个意见
8.12 晚上 Major Revise (20天期限)
8.30 With Editor
9.1 Under Review
9.3 两个审稿人意见返回
9.3 Decision in Process
9.8 Accept
投稿后拒稿在次投稿，希望可以给大家参考一下。

68 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：单体;中药;综述 经验分享：投稿审完，Decision in Process已经两个月了还没返回意见，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0 偏重的研究方向：单体;综述 经验分享：7.4 投稿 7.5 拒稿，建议修改标题，并补充 7.12 修改后Submitted to Journal 7.12 With Editor 7.12 Under Review 8.12 三个审稿人意见返回，Required Reviews Completed，最后回了三个意见 8.12 晚上 Major Revise (20天期限) 8.30 With Editor 9.1 Under Review 9.3 两个审稿人意见返回 9.3 Decision in Process 9.8 Accept 投稿后拒稿在次投稿，希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向：靶向治疗;药理;综述 经验分享：6月21号晚上投稿，综述看下什么情况，能中的话会回来评论另外想问下各位投稿稿件号都到多少了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0 偏重的研究方向：机制;药效;疗效 经验分享：required reviews completed状态持续5天了，好久了，是因为过元旦吗，有没有类似情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了，请问有类似情况的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=)]

2023-11-30 周大-Jagger 来自天津

请问这个投稿后，必须要每个作者邮件确认么？

24 0

[GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：单体;中药;综述 经验分享：投稿审完，Decision in Process已经两个月了还没返回意见，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0 偏重的研究方向：单体;综述 经验分享：7.4 投稿 7.5 拒稿，建议修改标题，并补充 7.12 修改后Submitted to Journal 7.12 With Editor 7.12 Under Review 8.12 三个审稿人意见返回，Required Reviews Completed，最后回了三个意见 8.12 晚上 Major Revise (20天期限) 8.30 With Editor 9.1 Under Review 9.3 两个审稿人意见返回 9.3 Decision in Process 9.8 Accept 投稿后拒稿在次投稿，希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向：靶向治疗;药理;综述 经验分享：6月21号晚上投稿，综述看下什么情况，能中的话会回来评论另外想问下各位投稿稿件号都到多少了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0 偏重的研究方向：机制;药效;疗效 经验分享：required reviews completed状态持续5天了，好久了，是因为过元旦吗，有没有类似情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了，请问有类似情况的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=)]

2023-06-22 少吃一口来自四川省

偏重的研究方向：靶向治疗;药理;综述
经验分享：6月21号晚上投稿，综述看下什么情况，能中的话会回来评论另外想问下各位投稿稿件号都到多少了吗？

38 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：单体;中药;综述 经验分享：投稿审完，Decision in Process已经两个月了还没返回意见，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0 偏重的研究方向：单体;综述 经验分享：7.4 投稿 7.5 拒稿，建议修改标题，并补充 7.12 修改后Submitted to Journal 7.12 With Editor 7.12 Under Review 8.12 三个审稿人意见返回，Required Reviews Completed，最后回了三个意见 8.12 晚上 Major Revise (20天期限) 8.30 With Editor 9.1 Under Review 9.3 两个审稿人意见返回 9.3 Decision in Process 9.8 Accept 投稿后拒稿在次投稿，希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向：靶向治疗;药理;综述 经验分享：6月21号晚上投稿，综述看下什么情况，能中的话会回来评论另外想问下各位投稿稿件号都到多少了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0 偏重的研究方向：机制;药效;疗效 经验分享：required reviews completed状态持续5天了，好久了，是因为过元旦吗，有没有类似情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了，请问有类似情况的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=)]

2023-01-02 ms9000001669050818

投稿命中率:50.0
偏重的研究方向：机制;药效;疗效
经验分享：required reviews completed状态持续5天了，好久了，是因为过元旦吗，有没有类似情况的？

52 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：单体;中药;综述 经验分享：投稿审完，Decision in Process已经两个月了还没返回意见，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0 偏重的研究方向：单体;综述 经验分享：7.4 投稿 7.5 拒稿，建议修改标题，并补充 7.12 修改后Submitted to Journal 7.12 With Editor 7.12 Under Review 8.12 三个审稿人意见返回，Required Reviews Completed，最后回了三个意见 8.12 晚上 Major Revise (20天期限) 8.30 With Editor 9.1 Under Review 9.3 两个审稿人意见返回 9.3 Decision in Process 9.8 Accept 投稿后拒稿在次投稿，希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向：靶向治疗;药理;综述 经验分享：6月21号晚上投稿，综述看下什么情况，能中的话会回来评论另外想问下各位投稿稿件号都到多少了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0 偏重的研究方向：机制;药效;疗效 经验分享：required reviews completed状态持续5天了，好久了，是因为过元旦吗，有没有类似情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了，请问有类似情况的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=)]

2022-02-07 148b3499m91暂无昵称

required reviews completed已经一周了，请问有类似情况的吗？

1 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2189895, encodeId=341f21898954f, content=偏重的研究方向：肿瘤 经验分享：刚接收了1篇，审稿1个月，给了2个月修改的时间，周末修回，3天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=babe1645573, createdName=不死鸟的飞翔, createdTime=Wed Feb 28 15:21:35 CST 2024, time=2024-02-28, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2156521, encodeId=0289215652162, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：单体;中药;综述 经验分享：投稿审完，Decision in Process已经两个月了还没返回意见，这正常吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45226154506, createdName=ms7000000804202809, createdTime=Thu Sep 07 11:07:06 CST 2023, time=2023-09-07, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2159101, encodeId=d6cd215910192, content=想问一下大家的手稿中关于qpcr部分满足了MIQE指南吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=28, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d538538122, createdName=ms6000002095545543, createdTime=Fri Sep 22 10:53:07 CST 2023, time=2023-09-22, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=1247862, encodeId=2248124e8629e, content=审稿速度:2.0 偏重的研究方向：单体;综述 经验分享：7.4 投稿 7.5 拒稿，建议修改标题，并补充 7.12 修改后Submitted to Journal 7.12 With Editor 7.12 Under Review 8.12 三个审稿人意见返回，Required Reviews Completed，最后回了三个意见 8.12 晚上 Major Revise (20天期限) 8.30 With Editor 9.1 Under Review 9.3 两个审稿人意见返回 9.3 Decision in Process 9.8 Accept 投稿后拒稿在次投稿，希望可以给大家参考一下。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220703/ac30326af85e40a198bd59fb829e58e1/640aec889c7a46399361ab5ac03a87e9.jpg, createdBy=720f2366630, createdName=待我慢慢, createdTime=Thu Sep 08 11:31:33 CST 2022, time=2022-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172199, encodeId=1f3521e21999e, content=请问这个投稿后，必须要每个作者邮件确认么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLho6ibOpwojItGTZU8OmLlGsyOSL7t2HVFaAIEZlIJqldoZQtUicuCs0xPlfVc8Tmj4ArWfgJJMs6w/132, createdBy=b6432539408, createdName=周大-Jagger, createdTime=Thu Nov 30 20:11:18 CST 2023, time=2023-11-30, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2144197, encodeId=ebdf214419e0a, content=偏重的研究方向：靶向治疗;药理;综述 经验分享：6月21号晚上投稿，综述看下什么情况，能中的话会回来评论另外想问下各位投稿稿件号都到多少了吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=26f41991655, createdName=少吃一口, createdTime=Thu Jun 22 01:00:54 CST 2023, time=2023-06-22, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2108507, encodeId=b3d1210850ea9, content=投稿命中率:50.0 偏重的研究方向：机制;药效;疗效 经验分享：required reviews completed状态持续5天了，好久了，是因为过元旦吗，有没有类似情况的？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=70838451007, createdName=ms9000001669050818, createdTime=Mon Jan 02 15:24:55 CST 2023, time=2023-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190882, encodeId=0156119088202, content=required reviews completed已经一周了，请问有类似情况的吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a11f5323517, createdName=148b3499m91暂无昵称, createdTime=Mon Feb 07 23:46:37 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=)]

2020-10-26 Charlo

10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。

214 14

展开14条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务